Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Idursulfase concentrate for infusion		NHSE commissioned.
Ifosfamide infusion		For hospital use only
Iloprost nebules		Hospital use only. NHS England commissioned.
Imatinib (Glivec®)	TA70 - Guidance on the use of imatinib for chronic myeloid leukaemia (partially updated by TA241 and TA251) TA86 - Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours TA326 - Imatinib for the adjuvant treatment of gastrointestinal stromal tumours TA209 - Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours TA426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia TA241 - Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance	Off-label use for melanoma with responsive c-KIT mutation
Imiglucerase injection		NHSE commissioned.
Imiquimod 5% cream (Aldara)
Indermil tissue adhesive
Indometacin (Indocid PDA)
Infliximab	TA329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab injection (Remicade®, Inflectra®, Remsima®)	TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA143 - Adalimumab , etanercept and infliximab for ankylosing spondylitis TA130 - Adalimumab , etanercept and infliximab for the treatment of rheumatoid arthritis TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.